Montpellier

• A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised
  2022-502126-40-00 5 HIV-1 infection
• Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis r … Pending
  2023-506420-93-00 4 Chronic recurrent multifocal osteomyelitis (CRMO)
• Efficacy and tolerance of nicotinamide supplementation during acute kidney injury: a prospective randomized double-blind trial Pending
  2023-508664-30-00 5 Acute kidney injury
• ESP-BACK : Erector Spinae Plane Block for acute low back pain Pending
  2024-511595-32-00 6 Acute low back pain
• LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction Pending
  2024-516167-86-00 5 Patients referred for an isolated or a combined surgical correction of
• BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis Pending
  2024-516849-39-01 5 antibiotic therapy in Sepsis
• Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros … Pending
  2024-518013-25-00 4 Idiopathic Pulmonary Fibrosis
• Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and /​ or MSI mCRC. (NIPISAFE) Pending
  2024-518138-10-00 4 Patients with DMMR and/or MSI metastatic colorectal cancer
• Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractli … Pending
  2024-518251-31-00 5 patients hospitalized for a septic shock with hypercontractlity
• A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Pending
  2024-519246-75-01 4 Patients With Muscle-Invasive Bladder Cancer
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• CHILURSO: Efficacy of Ursodeoxycholic Acid versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy Pending
  2025-521317-50-00 5 Cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Pending
  2025-521909-40-00 4 Patients with metastatic or locally advanced HER2-low triple-negative
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 5 Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m … Pending
  2025-524408-30-01 5 Metastatic hormone-sensitive prostate cancer
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• LUSPARA - Luspatercept in patients affected with rare inherited anemias Recruiting
  2024-520200-26-00 4 2026-02-13 Inherited anemias
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re

Showing 1–24 of 269 trials